Johnson & Johnson Partners With Sail Biomedicines On In Vivo CAR-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027
Johnson & Johnson Partners With Sail Biomedicines On In Vivo CAR-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day